Subconjunctival dexamethasone implant for non-necrotizing scleritis

BACKGROUND: The purpose of this study is to report the management of non-necrotizing anterior scleritis with a single-dose subconjunctival 0.7 mg dexamethasone implant (Ozurdex®, Allergan, Inc., CA, USA). Six patients with clinical diagnosis of non-necrotizing anterior scleritis (diffuse, sectorial,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nascimento, Heloisa, França, Maíra, García, Luciana Guadalupe, Muccioli, Cristina, Belfort, Rubens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605070/
https://www.ncbi.nlm.nih.gov/pubmed/23514443
http://dx.doi.org/10.1186/1869-5760-3-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605070/
https://www.ncbi.nlm.nih.gov/pubmed/23514443
http://dx.doi.org/10.1186/1869-5760-3-7

Ejemplares similares